The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: Rational and design of the French trials

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Guilhot, F ^a   Guerci, A ^a   Fiere, D ^a   Harousseau, J L ^a   Maloisel, F ^a   Bouabdallah, R ^a   Guyotat, D ^a   Rochant, H ^a   Najman, A ^a   Nicolini, F ^a   Colombat, P ^a   Abgrall, J F ^a   Ifrah, N ^a   Briere J ^a   Bauters, F ^a   Navarro, M ^a   Morice, P ^a   Bordessoule, D ^a   Vilque, J P ^a   Desablens, B ^a   Tertian, G ^a   Blanc, M ^a   Chastang, C ^a   Tanzer, J ^a   more..

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic myelogenous leukemia; Cytosine arabinoside; Interferon

Indexed keywords

ALPHA2B INTERFERON; ANTILEUKEMIC AGENT; CYTARABINE; INTERFERON;

ADULT; AGED; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; FRANCE; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTARABINE; DRUG TOLERANCE; FRANCE; HUMANS; HYDROXYUREA; INTERFERON ALFA-2B; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 15844424319     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Allan NC, Richards SM, Shepherd PCA, on behalf of the UK medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia. UK Medical Research Council randomised, multicenter trial of interferon-α 1 for chronic myeloïd leukemia : improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
2. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
3. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
4. Sokal JE, Gockerman JP, Bigner SH. Evidence for a selective anti-leukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Leukemia Res 1988; 12: 453-458.
5. Sokal JE, Leong SS, Gomez GA. Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer 1987; 59: 197-202.
6. Robertson MJ, Tantravahi R, Griffin JD, Canellos GP, Cannistra SA. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous influsion of low-dose cytarabine. Am J Hemat 1993; 43: 95-102.
7. Richman CM, Slapak CA, Toh B. Interferon protects normal human granulocyte/macrophage colony-forming cells from Ara-C cytotoxicity. J Biol Response Mol 1990; 9: 570-575.
8. Guilhot F, Dreyfus B, Brizard A, Huret JL, Tanzer J. Cytogenetic remission in chronic myelogenous leukemia using interferon α2a and hydroxyurea with or without low-dose cytosine-arabinoside. Leuk Lymph 1991; 4: 49-556.
9. Arthur CK, MA DFF. Combined interferon alpha-2a and cytosine-arabinoside as first line treatment for chronic myeloid leukemia. Acta Haematol 1993 (suppl. 1): 15-21.
10. Kantarjian HM, Keating MJ, Estey HE et al. Treatment of advanced stages of Philadelphia chromosome positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. J Clin Oncol 1992; 10: 772-778.